Panobinostat
Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 7, histone deacetylase 6, histone deacetylase 9, histone deacetylase 4, histone deacetylase 3, histone deacetylase 8, histone deacetylase 1, and histone deacetylase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Panobinostat lactate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FARYDAK | Secura Bio | N-205353 DISCN | 2015-02-23 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| farydak | New Drug Application | 2021-07-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
152 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia | D007951 | — | C92 | 11 | 7 | — | 1 | — | 15 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 11 | 5 | 1 | 1 | — | 14 |
| Primary myelofibrosis | D055728 | — | D47.4 | 4 | 3 | — | 1 | — | 6 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | 3 | — | 1 | — | 4 |
| Polycythemia vera | D011087 | — | D45 | 2 | 2 | — | 1 | — | 4 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 2 | 2 | — | 1 | — | 4 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 17 | 18 | 1 | — | 3 | 32 |
| Plasma cell neoplasms | D054219 | — | — | 16 | 16 | 1 | — | 3 | 30 |
| Lymphoma | D008223 | — | C85.9 | 13 | 19 | 1 | — | — | 29 |
| Myelodysplastic syndromes | D009190 | — | D46 | 7 | 6 | 1 | — | — | 11 |
| Preleukemia | D011289 | — | — | 7 | 6 | 1 | — | — | 11 |
| Hodgkin disease | D006689 | — | C81 | 6 | 4 | 1 | — | — | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 14 | 13 | — | — | — | 21 |
| Neoplasms | D009369 | — | C80 | 15 | 1 | — | — | — | 16 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 5 | — | — | — | 10 |
| Syndrome | D013577 | — | — | 7 | 6 | — | — | — | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 4 | — | — | — | 8 |
| Glioma | D005910 | EFO_0000520 | — | 6 | 4 | — | — | — | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 7 | 1 | — | — | — | 8 |
| Prostatic neoplasms | D011471 | — | C61 | 6 | 2 | — | — | — | 7 |
| Recurrence | D012008 | — | — | 5 | 3 | — | — | — | 7 |
| T-cell lymphoma | D016399 | — | — | 2 | 6 | — | — | — | 7 |
Show 59 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | — | — | — | — | 6 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Panobinostat |
| INN | panobinostat |
| Description | Panobinostat is a hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an antineoplastic agent and an angiogenesis modulating agent. It is a hydroxamic acid, a member of cinnamamides, a secondary amino compound and a methylindole. It is a conjugate base of a panobinostat(1+). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 404950-80-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL483254 |
| ChEBI ID | 85990 |
| PubChem CID | 6918837 |
| DrugBank | DB06603 |
| UNII ID | 9647FM7Y3Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC9
HDAC9
HDAC6
HDAC6
HDAC7
HDAC7
Organism
Homo sapiens
Gene name
HDAC9
Gene synonyms
HDAC7, HDAC7B, HDRP, KIAA0744, MITR
NCBI Gene ID
Protein name
histone deacetylase 9
Protein synonyms
HD7, HD7b, histone deacetylase 4/5-related protein, Histone deacetylase 7B, Histone deacetylase-related protein, MEF-2 interacting transcription repressor (MITR) protein, MEF2-interacting transcription repressor MITR
Uniprot ID
Mouse ortholog
Hdac9 (79221)
histone deacetylase 9 (Q99N13)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,343 documents
View more details
Safety
Black-box Warning
Black-box warning for: Farydak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,993 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use